AU2003295653B2 - Use of HMGB polypeptides for increasing immune responses - Google Patents

Use of HMGB polypeptides for increasing immune responses Download PDF

Info

Publication number
AU2003295653B2
AU2003295653B2 AU2003295653A AU2003295653A AU2003295653B2 AU 2003295653 B2 AU2003295653 B2 AU 2003295653B2 AU 2003295653 A AU2003295653 A AU 2003295653A AU 2003295653 A AU2003295653 A AU 2003295653A AU 2003295653 B2 AU2003295653 B2 AU 2003295653B2
Authority
AU
Australia
Prior art keywords
polypeptide
box
hmgb
antibody
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003295653A
Other languages
English (en)
Other versions
AU2003295653A1 (en
Inventor
Kevin J. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of AU2003295653A1 publication Critical patent/AU2003295653A1/en
Application granted granted Critical
Publication of AU2003295653B2 publication Critical patent/AU2003295653B2/en
Assigned to FEINSTEIN INSTITUTE OF MEDICAL RESEARCH reassignment FEINSTEIN INSTITUTE OF MEDICAL RESEARCH Request for Assignment Assignors: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE
Assigned to THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH reassignment THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH Request for Assignment Assignors: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003295653A 2002-11-20 2003-11-19 Use of HMGB polypeptides for increasing immune responses Ceased AU2003295653B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42784802P 2002-11-20 2002-11-20
US60/427,848 2002-11-20
PCT/US2003/036975 WO2004046338A2 (en) 2002-11-20 2003-11-19 Use of hmgb polypeptides for increasing immune responses

Publications (2)

Publication Number Publication Date
AU2003295653A1 AU2003295653A1 (en) 2004-06-15
AU2003295653B2 true AU2003295653B2 (en) 2007-08-16

Family

ID=32326601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295653A Ceased AU2003295653B2 (en) 2002-11-20 2003-11-19 Use of HMGB polypeptides for increasing immune responses

Country Status (6)

Country Link
US (1) US20060121047A1 (OSRAM)
EP (1) EP1567544A4 (OSRAM)
JP (1) JP2006506441A (OSRAM)
AU (1) AU2003295653B2 (OSRAM)
CA (1) CA2505682A1 (OSRAM)
WO (1) WO2004046338A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2008075788A1 (ja) * 2006-12-20 2008-06-26 Shino-Test Corporation ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
PL2525817T3 (pl) 2010-01-21 2018-01-31 Univ Arkansas Wektory szczepionkowe i sposoby wzmacniania odpowiedzi immunologicznych
AR084373A1 (es) 2010-03-29 2013-05-15 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas
EA030793B1 (ru) 2010-06-09 2018-09-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Рекомбинантный вакцинный вектор против инфекции campylobacter и способы усиления иммунного ответа на campylobacter и повышения устойчивости к инфекции campylobacter
AU2011299025B2 (en) * 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
JP6532407B2 (ja) 2013-02-14 2019-06-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CA2970529C (en) 2014-12-12 2019-07-02 The Feinstein Institute For Medical Research Treatment of hmgb1-mediated inflammation
EP3328429B1 (en) 2015-07-31 2025-07-16 The Research Institute at Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CN108367049A (zh) 2015-12-11 2018-08-03 海德堡吕布莱希特-卡尔斯大学 Pkm2调节剂和hmgb1的组合制剂
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3595445B1 (en) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020072993A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
US20250101204A1 (en) * 2022-02-28 2025-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for protecting against cell damage and inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
EP1577671A1 (en) * 1996-07-17 2005-09-21 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU2001245823A1 (en) * 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CZ20033402A3 (cs) * 2001-05-15 2004-10-13 Northáshore@Longáislandájewisháresearcháinstitute Použití fragmentů HMG jako protizánětlivých činidel
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20030014155A1 (en) * 2001-07-12 2003-01-16 Applied Material, Inc. High temperature substrate transfer robot

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Andersson et al, High mobility group 1 protein (HMG-1) stimulates pro-inflammatory cytokine synthesis in human monocytes, Journal of Experimental Medicine, vol.192 (4) 2000 *
Wen et al, A human placental cDNA clone that encodes non-histone chromosomal protein HMG-1, Nucleic Acid Research, vol.17 (3), 1989 *

Also Published As

Publication number Publication date
WO2004046338A3 (en) 2004-09-16
EP1567544A2 (en) 2005-08-31
CA2505682A1 (en) 2004-06-03
AU2003295653A1 (en) 2004-06-15
US20060121047A1 (en) 2006-06-08
JP2006506441A (ja) 2006-02-23
EP1567544A4 (en) 2009-07-22
WO2004046338A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2003295653B2 (en) Use of HMGB polypeptides for increasing immune responses
CN110461871B (zh) 白蛋白结合结构域融合蛋白
CA3042582C (en) Antibodies and polypeptides directed against cd127
KR100894359B1 (ko) 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
AU2002309829B2 (en) Use of HMG fragment as anti-inflammatory agents
AU635058B2 (en) Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
JP2005512507A6 (ja) 抗炎症剤としてのｈｍｇフラグメントの使用
US20030099647A1 (en) Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6576232B1 (en) IL13 mutants
JPH09501572A (ja) 精製された霊長類ｃｔｌａ−８抗原および関連する試薬
AU741419B2 (en) Ligand for herpes simplex virus entry mediator and methods of use
TW200916482A (en) Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same
JP2001503014A (ja) 防御免疫応答を増強するための方法
JP2009131263A (ja) ５０個のヒト分泌タンパク質
JP3223260B2 (ja) Ｔ細胞増殖促進因子
AU758576C (en) Chemokines with amino-terminal modifications
KR100483480B1 (ko) Ｍｈｃ 클래스 ⅰ과 ｍｈｃ 클래스 ⅱ 분자에 결합하는,ｎｙ-ｅｓｏ-1의 아미노산 서열에 상응하는 분리된펩티드, 및 그것의 사용
US20040156851A1 (en) HMGB1 combination therapies
JP2023145622A (ja) ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５
JP2009280620A (ja) 哺乳動物ランゲルハンス細胞抗原に対する抗体およびそれらの使用
CA2386248A1 (en) Il13 mutants
JP2001231578A (ja) Ｉｌ−１ファミリーに属する蛋白質
JP2003508525A (ja) 抗腫瘍抗体、タンパク質、及びそれらの使用
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
CN119630417A (zh) 抗原组合物、抗原表达用组合物及抗体组合物

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

Free format text: FORMER NAME: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE

TC Change of applicant's name (sec. 104)

Owner name: THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

Free format text: FORMER NAME: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired